Developments in Specialty Pharmacy®For Life Sciences
Stay Informed. Subscribe so you don’t miss out on the latest issue!
Subscribe so you don't miss out on updates.
We care about the protection of your data. Read our Privacy Policy.
Podcasts
- July 28, 2023, Why Rare-Ultra Orphan Therapies Need Early Market Access Planning
- June 26, 2023, Insights into the Cell & Gene Therapy Market: Podcast 2
- May 17, 2023, Insights into Rare Diseases, Cell & Gene Therapies Series: Podcast 1
- Game Theory Gone Wild: Co-pay Cards, Co-pay Accumulators, and Co-pay Maximizers, With Dea Belazi, PharmD, MPH, President and CEO of AscellaHealth
- Patient Journey Mapping Series: Podcast 4: How to Improve the Patient Experience & Why it Matters
- Patient Journey Mapping Series: Podcast 3: Navigating the Patient Journey in Specialty Pharmacy- From Evaluation Through Treatment
- Patient Journey Mapping Series: Podcast 2: Optimizing Specialty Pharmacy Health Outcomes
- Patient Journey Mapping Series: Podcast 1: Understanding Patient Care Coordination Across the Healthcare Spectrum
- Podcast Session with Michael Baldzicki, Chief Brand Officer, AscellaHealth, Find the Balance Point
- For Employers and Hospital Groups: Managing Specialty Pharmacy Spend & Maximizing Revenue
- Craig Caceci, Executive Vice President / Managing Director, Terebellum, part of AscellaHealth Family of Companies on eHealth Radio Network
- National Alliance of Healthcare Purchaser Coalitions Podcast Series: One on One - AscellaHealth
Webinars
Specialty & Rare Pipeline Digest™
Media Coverage & Press Releases
- Dea Belazi on Balancing Innovation and Healthcare Sustainability, HealthKey Summit 2024
- AscellaHealth Provides Specialty & Rare Pipeline Digest™ Recap: Navigating the Path to 2024 Groundbreaking Therapies
- FDA Warns on CAR-Ts, but Benefits Outweigh Risks for Now
- Cell and Gene Therapies, Biosimilars, Medical Benefit Drugs Are Areas to Watch Moving Forward
- AI Helps Streamline Some Health Care Tasks, Prompts Caution With Others
- Philadelphia business leaders address the life science industry
- 2023 Notable FDA Approvals Include Several Cell and Gene Therapies, First-Time Biosimilars
- Obesity Meds, Gene Therapies, NASH Drug Make Payers’ Cost Concern List
- Scrutiny of Accelerated Approval Continues as FDA Clamps Down
- AscellaHealth Expands Executive Team: Industry Veterans Lead Development and Implementation of End-to-End Payer Solutions and Pharmacy Operations to Control Specialty Spend
- AscellaHealth Identifies Key Trends Worth Watching in 2024: Forecasts Robust Outlook for Specialty Pharmacy Industry
- AscellaHealth Announces Strategic Global Joint Venture, Forming 4Merit Connections
- Another PI3K Inhibitor Will Be Withdrawn From U.S. Market
- AscellaHealth and Tilde Sciences Team Up to Launch Best-in-Class Patient-Centric Program for Increased Access to Daraprim and Enhanced Patient Outcomes
- Pipeline Digest Meets Specialty Drug Market Needs
- AscellaHealth Ranked Number 231 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
- Would Proposed Changes on Interchangeability Diminish Designation?
- Ensuring Timely, Secure Delivery of Therapies for Rare Diseases
- AscellaHealth Assesses New, Anticipated Specialty Treatments
- AscellaHealth President and CEO Dea Belazi Delivers Impactful Discussion at 2023 SIIA Annual Meeting: Specialty Pharmaceuticals and their Impact on Self-Insured Employers
- AscellaHealth Launches Q3 2023 Specialty & Rare Pipeline Digest™: Expert Resource for FDA Approval Status of Specialty Pharmaceuticals and Cell & Gene Therapies
- FDA Broadens Lonsurf Use in Colorectal Cancer
- Now That Humira Biosimilars Have Launched, What Are Lessons Learned for Stelara Biosimilars?
- Newer Drugs for ALL Are Hitting the U.S. Market, Potentially Filling Unmet Need
- AscellaHealth: Providing a Rare and Special Perspective
- NeuroSolv Therapeutics LLC Advances Spinal Cord Injury Treatment with Development of Perineline™ and Support from AscellaHealth LLC, a Global Healthcare & Specialty Pharmacy Solutions Company
- Ahead of Influx of Humira Biosimilars, One Manufacturer Reveals ‘Aggressive’ Pricing Strategy
- AscellaHealth Recognized Among Philadelphia Business Journal’s 2023 Best Places to Work
- From international expansion to IPOs, this year's PACT Enterprise Award winners have big plans
- AscellaHealth Expands Worldwide Market Position, Unifies Solutions Under One Global Brand, Brings A Rare and Special Perspective to the Industry
- AscellaHealth Launches Biopharmaceutical Educational Podcast Workshop Series, Partnering with National Association of Specialty Pharmacy & Pharmacy Podcast Network
- Specialty Drug Tiering, Indication Expansions, IRA Are Some Issues to Watch
- Humira Is Not Only Specialty Drug With Anticipated Biosimilars
- Expect Rare Disease, Cancer, Immunology Drugs to Have Big Impact
- More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
- FDA Approved Four New Gene Therapies, Other Novel Agents in 2022
- 2022 Saw Continued Approvals, Uptake of Biosimilars
- Specialty Pharmacy Trends to Watch in 2023 – Formulary Watch
- Seven Specialty Pharmacy Trends to Watch in 2023
- Potential of Gene and Cell Therapies for Patients with Rare/Orphan Diseases, Ensuring Access to Treatment
- PARP Inhibitors’ Data on Later Line Use in Ovarian Cancer Prompts Indication Withdrawals
- AscellaHealth - A Global Partner in Specialty Pharmacy Services for Life Sciences
Awards
- AscellaHealth Recognized by The Financial Times for Three Consecutive Years as One of “Americas' Fastest Growing Companies”
- AscellaHealth Ranks No. 46 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies
- EY Announces Dea Belazi, CEO and President, AscellaHealth, Entrepreneur Of The Year 2023 Greater Philadelphia Award Finalist
- PHL Inno - 5 Philadelphia-area companies make Deloitte's 2023 list of 500 fastest-growing tech firms
- AscellaHealth Ranked Number 231 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
- AscellaHealth Earns Merit-Based Philadelphia100 Award for Fourth Consecutive Year, Ranks #10 Among Fastest Growing, Private Companies in Philadelphia Region
- AscellaHealth Named 2023 Best Global Specialty Pharmacy & Healthcare Services Organisation
- AscellaHealth Earns Number One Spot for Fastest Growing Private Company and Number Two Spot on Philadelphia Business Journal “Soaring 76” Overall List of Fastest-Growing Companies
- For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent
- Announcing the recipients of the 2023 Philadelphia Titan 100–Bill Oldham
- Announcing the recipients of the 2023 Philadelphia Titan 100
- AscellaHealth Recognized Among Philadelphia Business Journal’s 2023 Best Places to Work
- AscellaHealth Recognized at 2023 PACT Enterprise Awards
- EY Announces Dea Belazi of AscellaHealth as an Entrepreneur Of The Year 2023 National Finalist
- AscellaHealth Captures Two Stevie Awards, Recognized as Fastest Growing Company and Marketing Department of the Year by 2023 American Business Awards
- Dea Belazi recognized by PACT 2022 Enterprise Awards as Life Sciences & Healthcare CEO Finalist
- AscellaHealth Recognized for Two Consecutive Years as One of “Americas' Fastest Growing Companies” by The Financial Times
- AscellaHealth Ranks No. 48 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies
- AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
- AscellaHealth Earns Merit-Based Philadelphia100 Award for Third Consecutive Year, Ranks Among Fastest Growing, Private Companies in Philadelphia Region
- AscellaHealth Earns Spot on Philadelphia Business Journal “Soaring 76” List of Fastest-Growing Companies
- AscellaHealth Named National Association of Specialty Pharmacy (NASP) Strategic Channel Partner of the Year
- AscellaHealth and Dea Belazi honored in 2022 Fire Awards
- Dea Belazi Named 2022 Titan 100 Award, Recognizing Philadelphia’s Top 100 CEO’s & C-level Executives
- AscellaHealth Recognized by Financial Times Fastest Growing Companies 2022
- AscellaHealth Ranks Among Prestigious 2021 Inc. Magazine's 5000 Honorees: One of the Country's Fastest Growing Private Companies
- AscellaHealth Earns Merit-Based Philadelphia100 Award for Second Consecutive Year, Ranks Among Fastest Growing, Private Companies in Philadelphia Region
- Philadelphia Business Journal Names AscellaHealth President and CEO Dea Belazi Among Top Honorees for Philadelphia Region's Most Admired CEOs